Trial Profile
Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms ZOSTER041
- Sponsors GlaxoSmithKline; GSK
- 07 Mar 2019 Primary endpoint of number of subjects with a vaccine response for anti-gE humoral immunogenicity has been met, according to results published in the Clinical Infectious Diseases.
- 07 Mar 2019 Results published in the Clinical Infectious Diseases
- 07 Oct 2018 Results presented at the IDWeek 2018